Protagonist Therapeutics Inc
XBER:PGF
Protagonist Therapeutics Inc
XBER:PGF
Price:
75
EUR
Market Closed
Market Cap:
€2.9B
Relative Value
The Relative Value of one
PGF
stock under the Base Case scenario is
hidden
EUR.
Compared to the current market price of 75 EUR,
Protagonist Therapeutics Inc
is
hidden
.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
PGF Relative Value
HIDDEN
Multiples Across Competitors
PGF Competitors Multiples
Protagonist Therapeutics Inc Competitors
Protagonist Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Protagonist Therapeutics Inc
XBER:PGF
|
6.4B EUR | 138.3 | -48.9 | -36.9 | -36.6 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
365.8B USD | 5.9 | 86.4 | 14.4 | 20 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
187.3B USD | 5.1 | 24.2 | 14.1 | 14.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
172B USD | 5.8 | 20.1 | 12.6 | 15.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
116.2B USD | 9.6 | 29.3 | 22 | 23 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
77.6B USD | 5.4 | 17.2 | 12.7 | 14.4 | |
| AU |
|
CSL Ltd
ASX:CSL
|
66.7B AUD | 3.1 | 33.9 | 11.2 | 14.1 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
41.8B USD | 11.3 | 133.5 | 74.7 | 83 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
